Phase 3 Readout~month
Phase 3 Topline: ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects A
- Company
- Sanofi (SNY)
- Drug
- fitusiran
- Indication
- Hemophilia
Other upcoming events for SNY
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Eff
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Eff
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Modified Double-blind, Multi-center Study of the Immunogenicity and Safety of an Investig
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator Stu
Phase 3 ReadoutPhase 3 Topline: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B,
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.